Not yet recruitingPriority 4 · Lower priorityNCT05923502
(CHANT)Real World Study of Duvelisib in the Treatment of Non-Hodgkin's Lymphoma (NHL)
Plain-language summary
This trial is testing duvelisib (an oral PI3K inhibitor) for patients with various types of peripheral T-cell lymphoma (PTCL) whose disease has come back or stopped responding to prior treatment. The study looks at both safety and how well the treatment controls the lymphoma. This trial does not currently have sites in the United States. The trial is not yet open for recruitment.
Who can join (key eligibility)
- Age 18 Years or older
- Lymphoma came back or did not respond to prior treatment
- Must be well enough for treatment (adequate performance status)
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
Duvelisib (DRUG): This is a real-word. The treatment options are individualized according to the diagnosis and treatment experience of doctors in each center, diagnosis and treatment specifications and individual conditions of patients.
Duvelisib
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details